FREE Case Review (866) 588-0600

Two New Invokana Amputation Lawsuits Filed in New Jersey

Two diabetes patients who had a leg amputated below the knee after taking Invokana (generic: canagliflozin) have filed a products liability lawsuit against Janssen Pharmaceuticals.

Two recent lawsuits filed in New Jersey State Court have brought renewed attention to the amputation risk associated with Janssen Pharmaceuticals’ type 2 diabetes medicine Invokana (generic: canagliflozin).

Free Confidential Lawsuit Evaluation: If you or a loved one has been injured by the side effects of Invokana, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer and our lawyers can help.

What’s the Problem?

January 4, 2018 – Both plaintiffs in the new cases were forced to have a foot and leg amputated below the knee after less than 1 year after beginning treatment with Invokana, according to Ring of Fire. Meanwhile, many physicians have weaned their diabetic patients off the drug while others have used a “wait and see” approach.

One of the plaintiffs is a 60-year-old man who started using Invokana in January 2017. Within 12 months, the man lost his left foot and right leg below the knee, according to the lawsuit. The other complaint was filed by a 53-year-old man who was required to undergo a below-knee amputation of his right leg in December 2015 after beginning a regimen of the drug in April 2015.

Both plaintiffs have since discontinued treatment with Invokana in favor of diabetes medicines with fewer side effects, according to the lawsuits. The complaints allege that Johnson & Johnson subsidiary Janssen Pharmaceuticals knew that Invokana could increase the risk of amputation, yet chose to keep this information secret in an effort to maximize profits.

In May 2016, the U.S. Food & Drug Administration (FDA) issued a Drug Safety Alert in response to an interim analysis of the Canagliflozin Cardiovascular Assessment Study (CANVAS), which identified a doubled risk for leg and foot amputations in patients treated with canagliflozin (the active ingredient in Invokana and Invokamet) compared to patients who took a placebo. Specifically, the study indicated that the rate of amputations per every 1000 patients was equivalent to 7 for 100 mg/day and 5 for 300 mg/day of canagliflozin compared with 3 per 1000 patients taking placebo.

A year after the alert was issued, FDA concluded that diabetes patients who take Invokana or Invokamet are twice as likely to have their foot or toe amputated. As a result of these findings, the agency required that both medications carry a boxed warning regarding the amputation risk.

Do I Have an Invokana Lawsuit?

The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Invokana lawsuits. We are handling individual litigation nationwide and currently accepting new amputation and diabetic ketoacidosis (DKA) cases in all 50 states.

Free Case Evaluation: Again, if you were harmed by Invokana side effects, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.

Free Confidential Case Evaluation

Verified 100% Secure SiteTo contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 588-0600.
Awards & recognition